Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie